ENDRA Life Sciences (NASDAQ:NDRA) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Barclays Maintains Overweight on Arista Networks, Raises Price Target to $177
Barclays analyst Tim Long maintains Arista Networks (NYSE:ANET) with a Overweight and raises the price target from $165 to $177.